Blue Door Asset Management LLC Takes Position in Hologic, Inc. $HOLX

Blue Door Asset Management LLC acquired a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 161,500 shares of the medical equipment provider’s stock, valued at approximately $10,523,000. Hologic makes up about 5.4% of Blue Door Asset Management LLC’s holdings, making the stock its 7th largest position. Blue Door Asset Management LLC owned about 0.07% of Hologic as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC acquired a new stake in shares of Hologic in the 2nd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd boosted its position in Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares in the last quarter. Loomis Sayles & Co. L P purchased a new stake in Hologic during the second quarter worth $33,000. Zions Bancorporation National Association UT purchased a new position in shares of Hologic in the first quarter valued at $34,000. Finally, Cromwell Holdings LLC raised its stake in shares of Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 436 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. BNP Paribas Exane downgraded shares of Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 target price for the company. in a report on Friday, November 21st. Morgan Stanley raised their price objective on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Stephens downgraded Hologic from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $78.00 to $76.00 in a research report on Wednesday, October 22nd. Argus increased their target price on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a report on Friday, September 19th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Five investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $79.29.

Insider Buying and Selling

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This represents a 13.52% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.88% of the stock is owned by corporate insiders.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $74.83 on Thursday. The business has a 50-day moving average of $72.74 and a two-hundred day moving average of $68.11. The firm has a market capitalization of $16.68 billion, a PE ratio of 30.17, a P/E/G ratio of 2.12 and a beta of 0.70. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $77.32. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the previous year, the business posted $1.01 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.